Compound News and Research

RSS

Review of Memantine for Alzheimer's

In a study published this month in the Journal of Alzheimer's Disease, researchers from the University of Aberdeen report that the drug memantine, used for the treatment of Alzheimer's disease and praised as "the first and only representative of a new class of Alzheimer drugs" works in fact similar to other existing compounds, and is beneficial only in a narrow concentration range.

11 Jan 2008

Bio-identical hormone replacement therapies targeted by FDA

The U.S. Food and Drug Administration (FDA) sent letters warning seven pharmacy operations that the claims they make about the safety and effectiveness of their so-called "bio-identical hormone replacement therapy," or "BHRT" products are unsupported by medical evidence, and are considered false and misleading by the agency.

10 Jan 2008

Soybeans for hot flashes

Researchers at Beth Israel Deaconess Medical Center (BIDMC) have found that a compound in soybeans is effective in reducing the frequency and severity of hot flashes in menopausal women.

10 Jan 2008

Researchers trigger insulin production in diabetic mice

If the human body were a stage, then proteins would rank among the lead actors in the play we call "Life."

9 Jan 2008

NicOx extends ophthalmology agreement with Pfizer

NicOx S.A. has announced it has signed an extension of its March 2006 collaboration agreement, which grants Pfizer Inc the exclusive right to apply its proprietary nitric oxide-donating technology to drug discovery research in the field of ophthalmology.

9 Jan 2008

Table-top device prevents potential errors in children's medications

A device designed to eliminate mistakes made while mixing compounds at a hospital pharmacy was 100 percent accurate in identifying the proper formulations of seven intravenous drugs.

9 Jan 2008

Rib-X Pharmaceuticals initiates two separate Phase II clinical trials for antibiotic compound

Rib-X Pharmaceuticals, Inc. has announced the enrolment of the first patients in two separate Phase 2 clinical trials.

7 Jan 2008

Daiichi Sankyo, Lilly submit NDA for investigational antiplatelet drug, Prasugrelin U.S.

Daiichi Sankyo Company, Limited and Eli Lilly and Company have announced that on Wednesday, Dec. 26, 2007, they submitted a New Drug Application (NDA) for prasugrel to the U.S. Food and Drug Administration (FDA).

7 Jan 2008

Everyone carries at least 1 type of pesticide

A study carried out by researchers from the Department of Radiology and Physical Medicine of the University of Granada, in collaboration with the Andalusian School of Public Health (Escuela Andaluza de Salud Publica), found that 100% of Spaniards analyzed had at least one kind of persistent organic compound (POC's), substances internationally classified as potentially harmful to one's health, in their bodies.

7 Jan 2008

Novel anti-tumor compound

Researchers at Emory University have developed a novel anti-tumor compound that represents a distinct strategy: targeting one of the most important "intercept points" for cancer cells.

4 Jan 2008

New hope for Batten disease sufferers

Investigators at the University of Rochester Medical Center have uncovered a promising drug therapy that offers a ray of hope for children with Batten disease – a rare neurodegenerative disease that strikes seemingly healthy kids, progressively robs them of their abilities to see, reason and move, and ultimately kills them in their young twenties.

3 Jan 2008

New clue found to the cause of Parkinson's disease

A glitch in the mechanism by which cells recycle damaged components may trigger Parkinson's disease, according to a study by scientists at the Albert Einstein College of Medicine of Yeshiva University.

3 Jan 2008

Artificial viral shells for pinpoint drug delivery

Researchers at the Technion-Israel Institute of Technology and The Scripps Research Institute in California are designing an artificial viral shell as a valuable nano-container for pinpoint drug delivery, molecular computing components, and a host of other applications.

3 Jan 2008

Light powered platinum more targeted and powerful than similar cancer treatments

Researchers from the Universities of Warwick, Edinburgh, Dundee and the Czech Republic's Institute of Biophysics have discovered a new light-activated platinum-based compound that is up to 80 times more powerful than other platinum-based anti-cancer drugs and which can use "light activation" to kill cancer cells in much more targeted way than similar treatments.

28 Dec 2007

New patent law has consequences for the pharmaceutical industry

On 13th December 2007 a revised version of the European Patent Convention (EPC) came into force. This new law, known as EPC2000, has a number of consequences for the pharmaceutical industry and the way in which patent applications are examined.

20 Dec 2007

RNA interference therapy heals growth deficiency disorder in a live animal

A team of Vanderbilt researchers have demonstrated for the first time that a new type of gene therapy, called RNA interference, can heal a genetic disorder in a live animal.

20 Dec 2007

Eli Lilly and BioMS Medical announce licensing and development agreement

Eli Lilly and Company and BioMS Medical Corp. have announced that the two companies have entered into a licensing and development agreement granting Lilly exclusive worldwide rights to BioMS Medical's lead multiple sclerosis (MS) compound, MBP8298.

18 Dec 2007

New biochip technology could eliminate animal testing in chemicals and cosmetics industries

A new biochip technology could eliminate animal testing in the chemicals and cosmetics industries, and drastically curtail its use in the development of new pharmaceuticals, according to new findings from a team of researchers at Rensselaer Polytechnic Institute, the University of California at Berkeley, and Solidus Biosciences Inc.

18 Dec 2007

Agent orange chemical, dioxin, attacks the mitochondria to cause cancer

Researchers with the University of Pennsylvania School of Veterinary Medicine have demonstrated the process by which the cancer-causing chemical dioxin attacks the cellular machinery, disrupts normal cellular function and ultimately promotes tumor progression.

18 Dec 2007

Targeted therapy and chemotherapy shrinks breast cancer metastases in brain

A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber Cancer Institute investigators at the San Antonio Breast Cancer Symposium.

17 Dec 2007